SRR8943030
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.280
- G2M_CHECKPOINT+0.270
- PANCREAS_BETA_CELLS+0.260
- KRAS_SIGNALING_DN+0.220
- MYC_TARGETS_V2+0.200
- SPERMATOGENESIS+0.200
- MYOGENESIS+0.140
- HYPOXIA+0.070
- MITOTIC_SPINDLE+0.060
- CHOLESTEROL_HOMEOSTASIS+0.000
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.440
- PROTEIN_SECRETION-0.400
- UV_RESPONSE_DN-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.340
- ADIPOGENESIS-0.320
- PI3K_AKT_MTOR_SIGNALING-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- INTERFERON_GAMMA_RESPONSE-0.310
- ALLOGRAFT_REJECTION-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_JVW2JJ39 | high-grade glioma | — | 0.909 |
| 2 | MNG459 | — | — | 0.900 |
| 3 | SRR22247242 | — | cohortSC | 0.889 |
| 4 | BS_44A3ES23 | medulloblastoma | — | 0.878 |
| 5 | 266352 | EPN | EPN Tumor | 0.876 |
| 6 | BS_JT82QGXF | medulloblastoma | — | 0.875 |
| 7 | BS_4E1G7E3G | ATRT | — | 0.872 |
| 8 | C3N-03886 | — | cohortMD1 | 0.870 |
| 9 | BS_77317DY4 | medulloblastoma | — | 0.869 |
| 10 | R283 | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.070 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |